StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note released on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Performance
NASDAQ:PIRS opened at $13.60 on Thursday. Pieris Pharmaceuticals has a fifty-two week low of $6.20 and a fifty-two week high of $22.32. The firm has a market capitalization of $17.95 million, a PE ratio of -1.12 and a beta of 0.61. The stock’s fifty day moving average is $15.59 and its 200 day moving average is $14.88.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Featured Stories
- Five stocks we like better than Pieris Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- 3 Monster Growth Stocks to Buy Now
- Nebius Group: The Rising Star in AI Infrastructure
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
